Profile of efficacy and safety in the treatment of remittent-recurrent multiple sclerosis with interferon β-1b;Perfil de eficacia y seguridad en el tratamiento de la esclerosis multiple remitente-recurrente con interferon β-1b

Neurologia

Volumn 13, Issue 9, 1998, Pages 422-426

  Rio J ^a   Marzo, M E ^a   Tintore M ^a   Borras C ^a   Montalban X ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Beta interferon; Multiple sclerosis; Treatment

Indexed keywords

INTERFERON BETA SERINE;

ADULT; ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; SKIN MANIFESTATION;

EID: 0344026287     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995; 37:7-15.
2. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
3. Paty DW, Li DKB, the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-667.
4. Stone LA, Frank JA, Albert PS, Basch CN, Calabresi PA, Maloni H et al. Characterization of MRI response to treatment with Interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 1997; 49: 862-869.
5. Dayal AS, Jensen MA, Lledó A, Arnason BGW. Interferon-gamma secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology 1995; 45: 2.173-2.177.
6. 1b treatment decreases tumor necrosis factor-a and increases interleukin-6 production in multiple sclerosis. Neurology 1996; 46: 1.633-1.638.
7. Soto J, Sacristán JA, Alsar MJ, Galende I. Farmacovigilancia dentro de la industria farmacéutica: presente y future. Med Clin (Barc) 1996; 106: 665-669.
8. Neilly LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta 1-b. Neurology 1996; 46: 552-554.
9. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis. Ann Neurol 1983; 13: 227-231.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1.444-1.452.
11. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh JK. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
12. Logan-Clubb L, Stacy M. An open-labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis. J Neurosci Nursing 1995; 27: 344-347.
13. Mohr DC, Goodkin DE, Likosky W, Gatto W, Neilley LK, Griffin C et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Multiple Sclerosis 1996; 2: 222-226.
14. Grup d'Estudi d'Esclerosi Múltiple de València Ciutat. Interferon-beta 1B en el tratamiento de la esclerosis múltiple remitente-recurrente. Experiencia clínica del grupo de Valencia. Rev Neurol (Barc) 1997; 25: 1.876-1.879.
15. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996; 46: 12-18.
16. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995:45: 1.277-1.285.
17. Río J, Nos C, Marzo ME, Tintoré M, Montalban X. Low oral steroid use reduces flu-like symptoms at the onset of IFNβ-1b therapy in relapsing-remitting multiple sclerosis. Neurology 1998. En prensa.
18. Rudick RA, Sibley W, Durelli L. Treatment of multiple sclerosis with type I interferons. En: Goodkin DE, Rudick RA, editores. Multiple sclerosis. Advances in clinical trial design, treatment and future perspectives. Londres: Springer-Verlag, 1996; 223-250.